MedTrace Logo

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

NCT01055067 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-04-06

Study results available
· View outcomes & findings →

Summary

This is a multicenter, single-arm study for safety and efficacy.

Conditions

  • Non-CNS Germ Cell Tumors (Seminomas and Nonseminomas)

Interventions

DRUG

Tivantinib (ARQ 197)

Capsule, 120 mg, BID (360 mg), approximately 112 days

Sponsors & Collaborators

Principal Investigators

  • Clinical Study Leader · Daiichi Sankyo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-02
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • United States
  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01055067 on ClinicalTrials.gov